A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc.
Seagen Inc.
Seagen Inc.
Taiho Oncology, Inc.
University of Pittsburgh
Sanofi
City of Hope Medical Center
University of Pittsburgh
Merck Sharp & Dohme LLC
Inhibrx Biosciences, Inc
City of Hope Medical Center
Dana-Farber Cancer Institute
City of Hope Medical Center
Aduro Biotech, Inc.